Fig. 6

a. Forest plots of the pooled RRs for the grade 3 or higher hematological adverse events (including neutropenia, anemia, thrombocytopenia, and lymphopenia) of the patients with MM in the MAbs targeting CD38 group versus control group. The RR < 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the random effects model in the meta-analysis. b Forest plots of the pooled RRs for the grade 3 or higher non-hematological adverse events (including pneumonia, upper respiratory tract infection, diarrhea, and fatigue) of the patients with MM in the MAbs targeting CD38 group versus control group. The RR < 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis